[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-458660-105":59,"doc-detail-458660-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","faricimab-treat-and-extend-approach-for-neovascular-age-related-macular-degeneration-insights-from-real-world-clinical-practice","Faricimab treat-and-extend approach for neovascular age-related macular degeneration - insights from real-world clinical practice","","Prospective cohort evidence evaluates outcomes after switching to faricimab using a treat-and-extend (T&E) regimen in patients with neovascular age-related macular degeneration (nAMD). Eligible participants had prior anti-VEGF T&E treatment with treatment intervals that could not be extended beyond 12 weeks and at least 24 weeks follow-up; faricimab was given for at least 6 months. Primary endpoint was injection-to-injection treatment interval, with secondary assessment of best-corrected visual acuity change from baseline to last follow-up.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/faricimab-treat-and-extend-approach-for-neovascular-age-related-macular-degeneration-insights-from-real-world-clinical-practice/458660/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/faricimab-treat-and-extend-approach-for-neovascular-age-related-macular-degeneration-insights-from-real-world-clinical-practice/458660.png","ImageObject",300,407,{"name":92,"@type":93},"Marglet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What population was included in this study?","Question",{"text":113,"@type":114},"Consecutive patients with nAMD who previously received anti-VEGF treatment in a treat-and-extend regimen, with treatment intervals that could not be extended beyond 12 weeks, and with a minimum follow-up of 24 weeks.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What was the primary endpoint?",{"text":118,"@type":114},"The primary endpoint was the treatment interval (TI) between intravitreal injections (IVIs).",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings after switching to faricimab?",{"text":122,"@type":114},"Treatment intervals increased at subsequent time points while best-corrected visual acuity remained stable. No serious adverse events were reported, though longer follow-up is needed for confirmation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},458660,1790835041,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336477982702,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Ruiz-Medrano etal. International Journal of Retina and Vitreous (2026) 12:5  \n[https://doi.org/10.1186/s40942-025-00776-0](https://doi.org/10.1186/s40942-025-00776-0)  \nInternational Journal of Retina and Vitreous  \nRESEARCH Open Access  \nFaricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice  \nJorge Ruiz-Medrano 1,2*, Iulia Pana 1, María García-Zamora 1, Ignacio Flores-Moreno 1, Mariluz Puertas 1 and José Mª Ruiz-Moreno 1,2,3  \nAbstract  \nPurpose To evaluate the clinical outcomes ofthe switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD) .  \nMethods This prospective cohort study included consecutive patients with nAMD who had previously been treated with anti-VEGF agents in aT&E regimen, with treatment intervals (TI) that could not be extended beyond 12 weeks, and a minimum follow-up of 24 weeks. These patients were switched to faricimab therapy in aT&E regimen for at least 6 months. The primary endpoint was the TI between intravitreal injections (IVIs), and the secondary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to the last follow-up visit (LFUV) .  \nResults A total of 225 eyes from 188 patients were included, with a mean age of 79.6 ± 7.4 years. Previous anti-VEGF treatments included ranibizumab (n = 34), aflibercept (n = 144), brolucizumab (n = 6), and bevacizumab (n = 41) . TI1 (5 .9 ± 2.0 weeks) matched the prior treatment interval. Significant increases in treatment intervals were observed at subsequent time points (TI2: 8.2 ± 3.2 weeks, TI3: 10.1 ± 3.9 weeks, TI4: 10.7 ± 4.3 weeks, TI5: 9.9 ± 4.0 weeks, and TI6:  \n8.5 ± 4.4 weeks; p \u003C 0. 001) . BCVA remained stable, going from 0.41 ± 0.23 to 0.43 ± 0.24 (p = 0 . 0112) . The mean number of injections was 5.9 ± 1. 9, with a mean follow-up duration of 51.4 ± 11.8 weeks.  \nConclusions The switch to faricimab in aT&E regimen significantly increased treatment intervals maintaining BCVAin patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results.  \nHighlights  \n• Results from clinical trials have shown the safety and efficacy of faricimab for AMD patients  \n• Real-life patient often differ from those from clinical trials so results can seldom be extrapolated  \n• This study provides results of faricimab in pretreated neovascular AMD patients in real-world clinical practice  \n*Correspondence:  \nJorge Ruiz-Medrano [jorge.ruizmedrano@gmail.com](jorge.ruizmedrano@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nRuiz-Medrano et al. International Journal of Retina and Vitreous (2026) 12:5 Page 2 of 7  \n• Different factors (age, init","cbCaiiic1U72kMLT","https://ap.wps.com/l/cbCaiiic1U72kMLT","pdf",1092829,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background on nAMD and anti-VEGF therapy\n## Rationale for faricimab\n# Methods","[{\"question\":\"What population was included in this study?\",\"answer\":\"Consecutive patients with nAMD who previously received anti-VEGF treatment in a treat-and-extend regimen, with treatment intervals that could not be extended beyond 12 weeks, and with a minimum follow-up of 24 weeks.\"},{\"question\":\"What was the primary endpoint?\",\"answer\":\"The primary endpoint was the treatment interval (TI) between intravitreal injections (IVIs).\"},{\"question\":\"What were the main findings after switching to faricimab?\",\"answer\":\"Treatment intervals increased at subsequent time points while best-corrected visual acuity remained stable. No serious adverse events were reported, though longer follow-up is needed for confirmation.\"}]","Faricimab treat-and-extend approach for neovascular age-related macular degeneration - insights from real-world clinical practice | PDF",1790754004,18]